Stock Rating Downgrade
In the last week the Value Trend Rating for Acadia Pharmaceuticals Inc (NASDAQ: ACAD) weakened from C to D reflecting eroding fundamentals and low Appreciation Potential.
Recent Price Action
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock increased 1.9% on 12/15/23. The shares closed at $28.58. Moreover, exceptionally high trading volume at 267% of normal accompanied the advance. The stock has been strong relative to the market over the last nine months and has risen 31.2% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, ACAD is expected to be a major Value Builder.
Acadia Pharmaceuticals has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Acadia Pharmaceuticals has a very low Appreciation Score of 6 but a good Power Rating of 80, and the Negative Value Trend Rating results.
Be the first to comment